The Journal is included in Russian and International Library and Abstract Databases
Russain Science Index (Russia)
EBSCO
DOI Registration Agency (USA)

PATHOGENETIC MECHANISMS UNDERLYING THE DEVELOPMENT OF OSTEOATHROSIS AND THEIR CORRECTION PROCEDURES

Download full text PDF
Issue: 
7
Year: 
2016

Professor A. Maryanovsky, MD N.I. Pirogov Russian National Research Medical University, Moscow

Degenerative-dystrophic diseases of the joints and vertebral column rank first in the prevalence of locomotor system diseases. The paper considers approaches to the pathogenetic therapy for osteoarthritis using the well tested drugs that have been proven safe when used for a long time.

Keywords: 
traumatology and orthopedics
rheumatology
osteoarthritis
Zeel T



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Lozada C., del Rio E., Reitberg D. et al. A multi-center double-blind, randomized, controlled trial (db-RCT) to evaluate the effectiveness and safety of co-administered Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections versus IA placebo in patients with moderate-to-severe pain associated with OA of the knee // Arthritis Rheumatol. – 2014; 66 (suppl.): S1266.
  2. Lesiak A., Gottwald R., Weiser M. Skutecznosc kuracji preparatem Zeel T w iniekcjach dostawowych okolostawowych i domiesniowych w chorobie zwyrodnieniowej stawow // Medycyna Biologiczna. – 2001; 2: 30–6.
  3. Gottwald R., Weiser M. Treatment of osteoarthritis of the knee with Zeel T // Medicina Biológica. – 2000; 13 (4): 109–13
  4. Wodick R., Steininger K., Zenner S. The biological treatment of articular affections – results of a study conducted with 498 patients // Biologische Medizin. – 1993; 3: 127–35.
  5. Hieber F. Intra-articular treatment of osteoarthritis and post-traumatic arthralgia with Zeel // Fortschritte der Medizin. – 1971; 89 (18): 778–80.
  6. J6. äggi R., Würgler U., Grandjean F. et al. Dual inhibition of 5-lipoxygenase/cyclooxygenase by a reconstituted homeopathic remedy; possible explanation for clinical efficacy and favourable gastrointestinal tolerability // Inflamm. Res. – 2004; 53 (4): 150–7
  7. Birnesser H., Stolt P. The homeopathic preparation Zeel comp. N: A review 7. of the molecular and clinical data // Explore (NY). – 2007; 3 (1): 16–22.
  8. Tunon H., Olavsdotter C., Bohlin L. Evaluation of anti-inflammatory activity 8. of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis // J. Ethnopharmacol. – 1995; 48: 61–76.
  9. Basini G., Santini S., Bussolati S. et al. Sanguinarine inhibits VEGF-induced 9. Akt phosphorylation // Ann. N. Y. Acad. Sci. – 2007; 1095: 371–6.
  10. Basini G., Bussolati S., Santini S. et al. Sanguinarine inhibits VEGF-induced 10. angiogenesis in a fibrin gel matrix // Biofactors. – 2007; 29 (1): 11–8.
  11. Schmolz M. Transforming Growth Factor beta (TGF-11. ): eine neue Regelstrecke für antiphlogistische Therapien? // Biol. Med. – 2000; 29 (1): 31–4.
  12. Schmolz M., Heine H. Hom12. öopathische Substanzen aus der antihomotoxischen Medizin modulieren die Synthese von TGF-1 in menschlichen Vollblutkulturen // Biol. Med. – 2001; 30 (2): 61–5.
  13. Staniková M., Bély M., Švik K. et al. Effects of Zeel comp. on experimental osteoarthritis in rabbit knee // Rheumatologia. – 1999; 13 (3): 101–8.
  14. Weh L., Fr14. öschle G. Incubation in preparations as a means of influencing cartilage mechanics: a mechanical study // Biol. Therapy. – 1990; 8 (4): 91–3.
  15. Haseeb A., Haggi T. Immunopathogenesis of osteoarthritis // Clin. 15. Immunol. – 2013; 146 (3): 185–96.
  16. Bonnet C., Walsh D. Osteoarthritis, angiogenesis and inflammation // 16. Rheumatology. – 2005; 44: 7–16.Malemud C. Anti-cytokine therapy for osteoarthritis // Drugs Aging. – 2010; 17. 27 (2): 95–115.
  17. Fernadendes J., Materl-Pelletier J., Pelletier J. The role of cytokines in 18. osteoarthritis pathophysiology // Biorheology. – 2002; 39 (1–2): 237–46.
  18. Pearle A., Scanzello C., George S. et al. Elevated high-sensitivity C-reactive 19. protein levels are associated with local inflammatory findings in patients with osteoarthritis // Osteoarthritis Cartilage. – 2007; 15 (5): 516–23.
  19. Walsh D., Pearson C. Angiogenesis in the pathogenesis of inflammatory 20. joint and lung diseases // Arthritis Res. – 2001; 3: 147–52.
  20. Mentlein R., Pufe T. New functions of angiogenic peptides in osteoarthritic 21. cartilage // Curr. Rheumatol. Rev. – 2005; 1: 37–45
  21. Vane J., Botting R. Anti-inflammatory drugs and their mechanism of action 22. // Inflamm. Res. – 1998; 47 (Suppl. 2): 78–87.
  22. Park J., Pillinger M., Abramson S. Prostaglandin E2 synthesis and 23. secretion: the role of PGE2 synthases // Clin. Immunol. – 2006; 119 (3): 229–40.
  23. Giuliano F., Warner T. Origins of prostaglandin E2: involvements of 24. cyclooxygenase (COX)-1 and COX-2 in human and rat systems // J. Pharmacol. Exp. Ther. – 2002; 303 (3): 1001–6.
  24. Kawabata A. Prostaglandin E2 and pain – an update // Biol. Pharm. Bull. – 25. 2011; 34 (8): 1170–3.
  25. Adatia A., Rainsford K., Kean W. Osteoarthritis of the knee and hip. Part I: 26. aetiology and pathogenesis as a basis for pharmacotherapy // J. Pharm. Pharmacol. – 2012; 64 (5): 617–25.
  26. Pountos I., Georgouli T., Bird H. et al. Nonsteroidal anti-inflammatory drugs: 27. prostaglandins, indications and side-effects // IJICMR. – 2011; 3: 19–27.
  27. Heller A., Koch T. et al. Lipid mediators in inflammatory disorders // 28. Drugs. – 1998; 55 (4): 487–96.
  28. Leone S., Ottani A., Bertolini A. Dual acting anti-inflammatory drugs // Curr. 29. Top Med. Chem. – 2007; 7 (3): 265–75.
  29. Espanha M. Articular cartilage: structure and histochemical composition // 30. Acta Reumatol. Port. – 2010; 35 (5): 424–33
  30. Martel-Pelletier J., Boileau C., Pelletier J. et al. Cartilage in normal and 31. osteoarthritis conditions // Best Pract. Res. Clin. Rheumatol. – 2008; 22 (2): 351–84.
  31. Aigner T., Soeder S., Haag J. IL-132. and BMPs – interactive players of cartilage matrix degradation and regeneration // Eur. Cell. Mater. – 2006; 12: 49–56.
  32. Yasuda T., Poole A. A fibronectin fragment induces type II collagen 33. degradation by collagenase through an interleukin-1-mediated pathway // Arthritis Rheum. – 2002; 46: 138–48.
  33. Lozada C., del Rio E., Reitberg D. et al. Risk-benefit of co-administerd 34. Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections in patients with moderate-to-severe pain associated with OA of the knee (OAK) // Ann. Rheum. Dis. – 2015; 74 (Suppl. 2): Abstract THU0441.